(-)-Epinephrine (+)-bitartrate: A Benchmark Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research

Executive Summary: (-)-Epinephrine (+)-bitartrate is a non-selective adrenergic receptor agonist with high affinity for α₁, α₂, β₁, β₂, and β₃ receptors (EC₅₀ values: β₁ ≈10 nM, α₁ ≈5 nM, β₂ ≈8 nM) [APExBIO product page]. It is the first-line treatment for anaphylactic shock and acute bronchial asthma exacerbations [Shaker et al., 2023]. The compound is commonly used in vitro at 1 nM–10 μM and in vivo with dosing tailored by species and route. Reliable solubility (≥22.9 mg/mL in water, ≥16.66 mg/mL in DMSO) and well-characterized pharmacology ensure experimental reproducibility. Adverse effects and contraindications (e.g., pheochromocytoma, hyperthyroidism) are well-documented, underscoring the importance of correct application [DOI].

Biological Rationale

Epinephrine Bitartrate (L-Epinephrine Bitartrate), also known as Adrenaline Bitartrate, is an endogenous catecholamine and the primary mediator of the sympathetic nervous system's acute stress (fight-or-flight) response. It modulates cardiovascular, respiratory, and metabolic processes by activating adrenergic receptors on target cells [APExBIO]. The compound is crucial for inducing vasoconstriction, increasing cardiac output, elevating blood pressure, and promoting bronchodilation. These physiological effects are essential for research in cardiovascular disease, neurobiology, and cell signaling. As a non-selective agonist, (-)-Epinephrine (+)-bitartrate allows for comprehensive interrogation of adrenergic pathways in both in vitro and in vivo models.

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

This compound acts as a potent, non-selective agonist at multiple adrenergic receptor subtypes, including α₁, α₂, β₁, β₂, and β₃. Upon binding:

• α₁ activation induces smooth muscle contraction and vasoconstriction, raising systemic vascular resistance and blood pressure [Shaker et al., 2023].
• β₁ activation increases heart rate (chronotropy) and the force of myocardial contraction (inotropy).
• β₂ receptor engagement leads to bronchodilation and inhibition of mast cell mediator release.
• β₃ activation is involved in metabolic regulation, including lipolysis.

EC₅₀ values for receptor activation are approximately 10 nM for β₁, 5 nM for α₁, and 8 nM for β₂ receptors, ensuring high potency at physiologically relevant concentrations [APExBIO].

Evidence & Benchmarks

• The lifetime prevalence of anaphylaxis is 1.6%–5.1% in the general population (Shaker et al., 2023, DOI).
• Prompt intramuscular administration of epinephrine is the first-line intervention for anaphylactic shock (Shaker et al., 2023, DOI).
• In >90% of anaphylaxis cases, a single dose of epinephrine is sufficient for symptom resolution (Shaker et al., 2023, DOI).
• (-)-Epinephrine (+)-bitartrate demonstrates solubility ≥22.9 mg/mL in water and ≥16.66 mg/mL in DMSO at 25°C (APExBIO, product page).
• Common in vitro concentrations: 1 nM–10 μM for cell-based assays; in vivo dosing: 0.15–0.3 mg intramuscularly or 2–20 mg intranasally in canine models (APExBIO, product page).

Compared to the article Epinephrine Bitartrate: Strategic Leverage for Translational Research, which focuses on mechanistic insights, this article provides a more granular, quantitative overview with explicit clinical and laboratory parameters.

Applications, Limits & Misconceptions

(-)-Epinephrine (+)-bitartrate is employed in:

• Emergency treatment of anaphylactic shock and acute asthma exacerbations [Shaker et al., 2023].
• Adjuvant to local anesthesia to prolong effect and reduce bleeding.
• Cardiovascular disease, sympathetic nervous system, and neurobiology research [Related article; our article emphasizes clinical benchmarks and assay parameters].
• Cell signaling assays for dissecting adrenergic pathway dynamics.

Common Pitfalls or Misconceptions

• Misconception: All patients at risk for allergy require multiple epinephrine devices; in reality, 90% of anaphylaxis cases resolve with one dose [DOI].
• Limitation: Not suitable for patients with pheochromocytoma or hyperthyroidism due to risk of dangerous hypertension and arrhythmias.
• Misuse: Overdosing can lead to severe cardiovascular side effects, including arrhythmia and hypertensive crisis.
• Stability: Solution storage is not recommended for the long term; degradation can occur even at -20°C [APExBIO].
• Solubility: Insoluble in ethanol; ensure use of water or DMSO for dissolution.

For further troubleshooting and validated workflows in cell signaling and viability assays, see Epinephrine Bitartrate (SKU B1358): Reliable Solutions for Biomedical Research. This article extends those discussions by emphasizing clinical dosing and contraindications.

Workflow Integration & Parameters

APExBIO provides (-)-Epinephrine (+)-bitartrate (SKU B1358) as a research-grade, high-purity reagent. For in vitro work, dissolve at ≥22.9 mg/mL in water or ≥16.66 mg/mL in DMSO. Typical assay concentrations are 1 nM–10 μM, adjusted per cell type and endpoint. In vivo, dosing must be species- and route-specific: e.g., 0.15–0.3 mg intramuscularly for acute intervention, or 2–20 mg intranasally in canine models. Store powder at -20°C; avoid prolonged solution storage to prevent degradation. For protocol optimization and Q&A-driven troubleshooting, see Optimizing Cell Assays with (-)-Epinephrine (+)-bitartrate, which this article complements by providing clinical data and updated contraindications. Always verify batch documentation and follow APExBIO's guidance for maximum experimental reproducibility.

Conclusion & Outlook

(-)-Epinephrine (+)-bitartrate remains the reference adrenergic receptor agonist for cardiovascular and neurobiology research. Its predictable pharmacology, reliable solubility, and broad receptor affinity support its use in mechanistic studies and translational models. Clinical benchmarks confirm its central role in emergency medicine for anaphylaxis and asthma. Limitations and contraindications must be respected for safe, data-driven application. For detailed product information and batch QC, consult the APExBIO (-)-Epinephrine (+)-bitartrate product page.